Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Eugene Athan,James Baber,Karen Quan,Robert J Scott,Anna Jaques,Qin Jiang,Wen Li,David Cooper,Mark W Cutler,Elena V Kalinina,Annaliesa S Anderson,Kena A Swanson,William C Gruber,Alejandra Gurtman,Beate Schmoele-Thoma,Study C3671006 Investigator Group,Christopher Argent,Mark Arya,Paul Bird,Mark Bloch,Sheetal Bull,David Colquhoun,Gustinna De Silva,Sachin Deshmukh,Peter Eizenberg,Christopher Gilfillan,Elizabeth Gunner,Valerie Hiew,Amber Leah,Indika Leelasena,Jason Lickliter,Anthony McGirr,Rahul Mohan,Claire Morbey,Louise Murdoch,Mark Nelson,A Munro Neville,Matthew O'Sullivan,Christopher Rook,Marc Russo,Philip Ryan,Robert Scott,Sze Tai,Florence Tiong,Olga Voloshyna,Peter Wark

DOI: https://doi.org/10.1093/cid/ciad707

2024-05-15

Abstract:Background: Respiratory syncytial virus (RSV) and influenza are both typically seasonal diseases, with winter peaks in temperate climates. Coadministration of an RSV vaccine and influenza vaccine could be a benefit, requiring 1 rather than 2 visits to a healthcare provider for individuals receiving both vaccines. Methods: The primary immunogenicity objective of this phase 3, 1:1 randomized, double-blind, placebo-controlled study in healthy adults aged ≥65 years in Australia was to demonstrate noninferiority of immune responses with coadministration of the stabilized RSV prefusion F protein-based vaccine (RSVpreF) and seasonal inactivated influenza vaccine (SIIV) versus SIIV or RSVpreF administered alone, using a 1.5-fold noninferiority margin (lower bound 95% confidence interval >.667). Safety and tolerability were evaluated by collecting reactogenicity and adverse event data. Results: Of 1403 participants randomized, 1399 received vaccinations (median age, 70; range, 65‒91 years). Local reactions and systemic events were mostly mild or moderate when RSVpreF was coadministered with SIIV or administered alone. No vaccine-related serious adverse events were reported. Geometric mean ratios were 0.86 for RSV-A and 0.85 for RSV-B neutralizing titers at 1 month after RSVpreF administration and 0.77 to 0.90 for strain-specific hemagglutination inhibition assay titers at 1 month after SIIV. All comparisons achieved the prespecified 1.5-fold noninferiority margin. Conclusions: The primary study objectives were met, demonstrating noninferiority of RSVpreF and SIIV immune responses when RSVpreF was coadministered with SIIV and that RSVpreF had an acceptable safety and tolerability profile when coadministered with SIIV. The results of this study support coadministration of RSVpreF and SIIV in an older-adult population. Clinical trials registration: https://clinicaltrials.gov/study/NCT05301322.